Anzeige
❌
Mehr »
Dienstag, 14.07.2026 - Börsentäglich über 12.000 News
Time to Buy! Diese drei Kräfte treiben die Tiefsee-Exploration massiv an
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A41BEM | ISIN: US74907L4095 | Ticker-Symbol: 2EB0
Frankfurt
14.07.26 | 08:01
3,340 Euro
-2,34 % -0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
QUOIN PHARMACEUTICALS LTD ADR Chart 1 Jahr
5-Tage-Chart
QUOIN PHARMACEUTICALS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
3,5203,88015:30

Aktuelle News zur QUOIN PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome223GlobeNewswire (Europe)Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and EuropeFDA Expressed No Safety Concerns Over Study Design and Duration of...
► Artikel lesen
30.06.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome737GlobeNewswire (Europe)ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan...
► Artikel lesen
23.06.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report1SEC Filings
23.06.Quoin Pharma: FDA Conditionally Accepts QYLEKI As Proposed Brand Name For QRX0032RTTNews
23.06.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton Syndrome224GlobeNewswire (Europe)QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDAPivotal Phase 3 Study Expected to Initiate...
► Artikel lesen
18.06.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003233GlobeNewswire (Europe)Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN...
► Artikel lesen
04.06.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report1SEC Filings
04.06.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome1GlobeNewswire (USA)
QUOIN PHARMACEUTICALS Aktie jetzt für 0€ handeln
02.06.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome193GlobeNewswire (Europe)-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from...
► Artikel lesen
07.05.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report-SEC Filings
07.05.Quoin Pharmaceuticals, Ltd. - 10-Q, Quarterly Report-SEC Filings
07.05.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results 404GlobeNewswire (Europe)- Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome - Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW...
► Artikel lesen
30.04.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 20261GlobeNewswire (USA)
28.04.Quoin plant neue klinische Studien für topisches Rapamycin-Präparat bei seltenen Erkrankungen-Investing.com Deutsch
26.03.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report5SEC Filings
26.03.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results469GlobeNewswire (Europe)- Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory...
► Artikel lesen
26.03.FM Bank and Quoin Financial Bank migrate to Jack Henry5FinTech Futures
25.03.Quoin Pharmaceuticals Shares Rise 5% After Approval Path For QRX0033RTTNews
25.03.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome224GlobeNewswire (Europe)FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include...
► Artikel lesen
19.03.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 20263GlobeNewswire (USA)
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1